November 04, 2024
Developing treatments for people with mental health conditions
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH
September 16, 2024
Topline results from Boehringer's Phase III IPF Study
September 09, 2024
Positive results reported in HER2 mutated lung cancer
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New affordability initiative with GoodRx for our biosimilar
July 17, 2024
New effort to help improve C-R-M health outcomes
June 07, 2024
Results from Phase II MASH trial presented at EASL 2024
June 01, 2024
Boehringer inhalers now available at $35 a month for eligible patients
May 13, 2024
New agreement with Quallent expands biosimilar access
Media Contacts
Head, U.S. Communications Human Pharma
900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877
Boehringer Ingelheim Animal Health USA Inc.
U.S. Communications
Phone +1 (516) 527-5456